335 related articles for article (PubMed ID: 24953079)
1. Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura.
Wu N; Liu J; Yang S; Kellett ET; Cataland SR; Li H; Wu HM
Transfusion; 2015 Jan; 55(1):18-24. PubMed ID: 24953079
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity.
Cataland SR; Jin M; Lin S; Kennedy MS; Kraut EH; George JN; Wu HM
Br J Haematol; 2007 Nov; 139(3):486-93. PubMed ID: 17910638
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura.
Cataland SR; Jin M; Ferketich AK; Kennedy MS; Kraut EH; George JN; Wu HM
Br J Haematol; 2007 Jan; 136(1):146-9. PubMed ID: 17069579
[TBL] [Abstract][Full Text] [Related]
4. Treatment of thrombotic thrombocytopenic purpura.
Fontana S; Kremer Hovinga JA; Lämmle B; Mansouri Taleghani B
Vox Sang; 2006 May; 90(4):245-54. PubMed ID: 16635066
[TBL] [Abstract][Full Text] [Related]
5. Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura.
Barrows BD; Teruya J
Arch Pathol Lab Med; 2014 Apr; 138(4):546-9. PubMed ID: 24678685
[TBL] [Abstract][Full Text] [Related]
6. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
[TBL] [Abstract][Full Text] [Related]
7. Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma.
Isonishi A; Bennett CL; Plaimauer B; Scheiflinger F; Matsumoto M; Fujimura Y
Transfusion; 2015 Oct; 55(10):2321-30. PubMed ID: 26058519
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic thrombocytopenic purpura--the role of ADAMTS13 assay in clinical practice.
Duraković N; Radonić R; Gasparović V
Coll Antropol; 2010 Sep; 34(3):1087-91. PubMed ID: 20977108
[TBL] [Abstract][Full Text] [Related]
9. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.
Mori Y; Wada H; Gabazza EC; Minami N; Nobori T; Shiku H; Yagi H; Ishizashi H; Matsumoto M; Fujimura Y
Transfusion; 2002 May; 42(5):572-80. PubMed ID: 12084165
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience in treatment of thrombotic thrombocytopenic purpura--hemolytic uremic syndrome with 28 patients.
Vuclić D; Rajić Z; Savić N; Miković D; Budisin Z; Antonijević NM; Obradović S; Jevtić D; Bettoni G; Casoli G; Peyvandi F
Acta Chir Iugosl; 2013; 60(1):29-38. PubMed ID: 24669560
[TBL] [Abstract][Full Text] [Related]
12. Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.
Bentley MJ; Wilson AR; Rodgers GM
Vox Sang; 2013 Nov; 105(4):313-8. PubMed ID: 23662653
[TBL] [Abstract][Full Text] [Related]
13. Value of ADAMTS13 activity and inhibitor in the postmortem diagnosis of thrombotic thrombocytopenic purpura.
Dwyre DM; Dursteler B; Nashelsky M; Friedman KD; Raife TJ
J Clin Apher; 2009; 24(3):106-10. PubMed ID: 19253359
[TBL] [Abstract][Full Text] [Related]
14. The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.
Bentley MJ; Lehman CM; Blaylock RC; Wilson AR; Rodgers GM
Transfusion; 2010 Aug; 50(8):1654-64. PubMed ID: 20412532
[TBL] [Abstract][Full Text] [Related]
15. Thrombotic thrombocytopenic purpura in children.
Loirat C; Coppo P; Veyradier A
Curr Opin Pediatr; 2013 Apr; 25(2):216-24. PubMed ID: 23422353
[TBL] [Abstract][Full Text] [Related]
16. Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura.
Connell NT; Cheves T; Sweeney JD
Transfusion; 2016 Feb; 56(2):354-9. PubMed ID: 26456149
[TBL] [Abstract][Full Text] [Related]
17. Serial ADAMTS13 measurements during initial plasma exchange therapy guide decisions for management of unresponsive thrombotic thrombocytopenic purpura.
van der Veen BS; Besseling R; Hoogendoorn M
Transfusion; 2015 Oct; 55(10):2511-5. PubMed ID: 26308736
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration.
Elliott MA; Letendre L; Gastineau DA; Winters JL; Pruthi RK; Heit JA
Eur J Haematol; 2010 Jul; 85(1):43-50. PubMed ID: 20331741
[TBL] [Abstract][Full Text] [Related]
19. A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13.
Sato A; Hoshi Y; Onuma M; Sato R; Tsunematsu Y; Isonishi A; Matsumoto M; Fujimura Y; Imaizumi M
Pediatr Hematol Oncol; 2010 Feb; 27(1):53-8. PubMed ID: 20121555
[TBL] [Abstract][Full Text] [Related]
20. [Determination of the ADAMTS13 antigen and its activity in TTP patients and carriers].
Liu F; Feys HB; Dong NZ; Bai X; Vanhoorelbeke K; Deckmyn H; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):154-7. PubMed ID: 16792913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
